Abstract Beta (b)-thalassemia is the most frequently observed hereditary blood disorder in the world. It is characterized by deficiency of hemoglobin b-globin gene and is also a profoundly heterogeneous both at the molecular and clinical level. 
Introduction
Beta-thalassemia (b-Thal), is the most frequently observed hereditary blood disorder in the world and is characterized by deficiency of hemoglobin b-globin gene [1] . In the case of b-Thal, there is reduced (b ? type) or absent (b o type) synthesis of the beta chains of hemoglobin [1, 2] .
b-Thal clinically occurs in three main forms: major, intermedia and minor according to requirement of transfusion [3] . b-Thal major is characterized by completely inhibited synthesis of beta chains [4] so b-Thal major must be treated (generally transfusion therapy) otherwise 85 % of patients die in early childhood due to severe anemia [5] . b-Thal major phenotype has homozygotes or compound heterozygotes for b o or b ? genes [6] . In contrast to major type, b-Thal minor patients are carrier, only one allel has a mutation and other allel is normal, and have slight phenotype (except to dominantly inherited b-Thal [7] ). b-Thal intermedia clinically differs from major and minor ones with respect to necessity of transfusion. The degree of anemia for b-Thal major is more aggravated than the grade of anemia for bThal intermedia [5, 8] . The genotype of b-Thal intermedia is mostly homozygotes or compound heterozygotes [6] .
b-Globin gene is found in b-globin locus which is localized on the short region of chromosome 11(11p15.4) and composed of five genes (b-globin and beta-like genes span 70 kb) [7] . b-Globin gene spans 1,600 bp and encodes 146 amino acid residues, and consists of three exons and two introns (intervening sequences, IVS). Exon 1 encodes for amino acid residues from 1 to 29 and also encodes the first two bases of codon 30, exon 2 encodes the last base of codon 30 and amino acids from 31 to 104 and exon 3 codes for amino acids from 105 to 146 [7] . In addition, 5 0 flanking, promoter, splicing and 3 0 untranslated (3 0 -UTR) regions also are important for b-globin protein activity [7, 9] .
In this retrospective study, 89 b-thalassemic patients from 2 months to 16 years of age enrolled to Medical School Research and Training Hospital, University of Gaziantep, Turkey were included. Genomic sequence of b-globin gene was scanned for mutations working direct DNA sequence analysis. This assay enables more comprehensive detection of rare and novel mutations [3] . We reported the number and the frequencies of known mutations, and type of b-Thal mutations and then carried out mutation analysis of b-Thal in Gaziantep of Turkey. In addition, we defined a novel mutation located in promoter region of b-globin gene and informed about the b-Thal phenotype.
Materials and Methods

Patient Selection
This study included 89 patients who were enrolled Department of Pediatric Hematology between 2009 and 2013 in Medical School Research and Training Hospital, University of Gaziantep, which serves patients from Southeast part of Turkey and in this part of Turkey. b-Thal is a significant public health problem in South-east part of Turkey. 89 b-Thal patients (ranging from 2 months to 16 years of age) were included into the study group. The study was approved by the Institutional Review Board of Faculty of Medicine in University of Gaziantep.
Mutation Analysis 89 b-Thal patients were included in this study. Genomic DNA was isolated from peripheral blood samples using the QIAamp DNA Blood Mini Kit (Qiagen Sample and Assay Technologies, Hilden, Germany). b-Globin gene was amplified by using polymerase chain reaction (PCR) Seq finder sequencing system HBB Kit (Wollerau, Switzerland). PCR was performed in 25 ll reaction volumes containing 12.5 ll master mix, 2 ll of primer mix (forward and reverse), 2 ll distilled water, 4 ll GC enhancer, 2.5 ll of genomic DNA and 0.2 ll Taq polymerase. PCR reactions were carried out in a GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA, USA) and cycling conditions were for 95°C, 10 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 59°C for 90 s, and elongation at 72°C for 60 s and a final elongation at 72°C for 7 min. The samples were purified by ExoSAP-IT (Thermo Fisher Scientific, Waltham, MA, USA) and sequenced with the 31309l Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Genomic and amino acid sequences for b-globin gene was obtained from Ensemble: ENSG00000244734, ENSP00000333994.3 b-Thal is classified into major, minor, intermedia. Table 1 Table 2 . In addition, Table 2 lists the molecular features of mutations, rs numbers and HGVS codes. The mutations were found in exons, intron regions and also promoter regions. The ratio of b o /b ? detected, Thalassemia mutations was 1.18, except novel mutation. Moreover, a novel mutation (HBB:c.-80delT) was and tagged by rs397509430. The novel mutation gave rise to b-Thal major phenotype for this patient. The hemoglobin levels for the patient were HbA 1 : 45.3 %, HbA 2 : 3.7 % and HbF: 51 %, respectively and also first hemoglobin (Hb) concentration was 7.4 g/dl. He has received blood transfusions in 3 weeks regularly. The patient does not have a laparoscopic splenectomy. The patient was admitted to the bone marrow transplantation. The parents are heterozygous for this mutation and their HbA 2 levels were approximately 4 %.
Results
DNA
Discussion
b-Thal, is the most frequently observed hereditary blood disorder in the world, is characterized by deficiency of hemoglobin b-globin gene and also is a profoundly heterogeneous, both at the molecular and clinical level [1, 10] . Approximately 300 different b-globin gene mutations for b-Thal have been reported and 40 of them are common in Turkey [11] . The first b-thalassemia study for Turkey was published in 1985 [1, 12] . When considering the distribution of these mutations, it is seen that heterogeneity increases from the western part of the country to the east [13] . The distributions of most common mutations in Southeastern part of Turkey are IVS I-110, IVS I-6, CODON 15, IVS I-1 and others which have frequencies approximately 25, 15, 10, 5, 60 %, respectively [13] .
In our study, we have identified 16 different b-Thal mutations in 89 patients; the mutations were noted in 37.5 % of other studies reported for b-Thal mutations from Turkey [11, 13, 14] . In addition, we detected a novel bglobin gene mutation located in the promoter region of the gene and found b-Thal major phenotype.
Three most frequent b-globin gene mutations were reported in 62.16 % of our study, and the most common mutation was detected as IVS I-110 G[A, similar to previous reports [1, 11, 15] . The other most common mutations of IVS I-1 G[A (13.51 %) and, IVS I-6 T[C (10.81 %) were similar to previous report. The other studies in Turkey indicated that second most common mutations was CODON 8 (-AA) and also it is most common mutation in Azerbaijan [1, 11] , but other previous study detected as 6.1 % [13] ? type and this mutation causes severely lesions so homozygous or compound heterozygous combinations for the mutations reasons b-Thal major form [13] . In this study the majority of b ? type patients also contained IVS I-110 G[A lesion.
Homozygous and compound heterozygous individuals have usually b-Thal major and intermedia phenotype [6] . However, in our cases, two compound heterozygous patients were found as b-Thal minor (see Table 1 ). In addition, the same mutation can be seen in both b-Thal major and intermedia [11] just as we found in our study. Because of mentioned conditions above, b-Thal phenotype can be influenced by not only the b-globin gene mutations but also other factors, e.g., a/b-globin chain imbalance, changes in other genes involved in bilirubin metabolism and iron absorption [13] . We described a novel mutation (-30 (-T)) for b-globin gene located in the TATA box (positions -28 to -31) which is cis acting element for promoter region and bound transcription factors [7] so the mutation may prevent to the binding to transcription factors in the TATA box in order to reduction or inhibition of transcription. This mutation gives rise to b-Thal major in homozygous form so transcription of bglobin gene is severely affected. The mutation types (b o or b ? ) are not known for this mutation and it will be investigated.
Conclusion
As a conclusion, in this retrospective study, we determined the distributions of b-Thal mutations in south-east part of Turkey which were all studied in Gaziantep University. 16 different mutations were found, and a novel mutation was reported additionally. Correlation between this novel mutation and clinical manifestations were established so that detection of novel mutation was significant for literature.
